Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study.
Nicolas DelanoyDebbie G J RobbrechtMario EisenbergerOliver SartorRonald de WitFlorence MercierChristine Geffriaud-RicouardJohann de BonoStephane Marie OudardPublished in: Cancers (2021)
This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.
Keyphrases
- poor prognosis
- phase iii
- chronic pain
- end stage renal disease
- prostate cancer
- long non coding rna
- newly diagnosed
- clinical trial
- small cell lung cancer
- chronic kidney disease
- squamous cell carcinoma
- open label
- neuropathic pain
- ejection fraction
- randomized controlled trial
- prognostic factors
- spinal cord
- radical prostatectomy
- postoperative pain